Literature DB >> 12910247

Molecular viral oncology of hepatocellular carcinoma.

Timothy M Block1, Anand S Mehta, Claus J Fimmel, Robert Jordan.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer, but the third leading cause of cancer death, in the world, with more than 500,000 fatalities annually. The major etiology of HCC/liver cancer in people is hepatitis B virus (HBV), followed by hepatitis C virus infection (HCV), although nonviral causes also play a role in a minority of cases. Recent molecular studies confirm what was suspected: that HCC tissue from different individuals have many phenotypic differences. However, there are clearly features that unify HCC occurring in a background of viral hepatitis B and C. HCC due to HBV and HCV may be an indirect result of enhanced hepatocyte turnover that occurs in an effort to replace infected cells that have been immunologically attacked. Viral functions may also play a more direct role in mediating oncogenesis. This review considers the molecular and cellular mechanisms involved in primary hepatocellular carcinoma, using a viral perspective.

Entities:  

Mesh:

Year:  2003        PMID: 12910247     DOI: 10.1038/sj.onc.1206557

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  173 in total

1.  The analysis of CD45 isoforms expression on HBV-specific T cells after liver transplantation.

Authors:  Lelin Pan; Wenjin Zhang; Jian Zhang; Lin Zhou; Lanjuan Li; Shusen Zheng
Journal:  Med Oncol       Date:  2011-01-30       Impact factor: 3.064

2.  pIgR: frenemy of inflammation, EMT, and HCC progression.

Authors:  Nathalie Sphyris; Sendurai A Mani
Journal:  J Natl Cancer Inst       Date:  2011-10-24       Impact factor: 13.506

3.  The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma.

Authors:  Mengjun Wang; Karthik Devarajan; Amit G Singal; Jorge A Marrero; Jianliang Dai; Ziding Feng; Jo Ann S Rinaudo; Sudhir Srivastava; Alison Evans; Hie-Won Hann; Yinzhi Lai; Hushan Yang; Timothy M Block; Anand Mehta
Journal:  Cancer Prev Res (Phila)       Date:  2015-12-28

Review 4.  Glycosylation and liver cancer.

Authors:  Anand Mehta; Harmin Herrera; Timothy Block
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

5.  LncRNA-NEF antagonized epithelial to mesenchymal transition and cancer metastasis via cis-regulating FOXA2 and inactivating Wnt/β-catenin signaling.

Authors:  Wei-Cheng Liang; Jia-Lin Ren; Cheuk-Wa Wong; Sun-On Chan; Mary Miu-Yee Waye; Wei-Ming Fu; Jin-Fang Zhang
Journal:  Oncogene       Date:  2018-01-09       Impact factor: 9.867

6.  Curcumin combined with glycyrrhetinic acid inhibits the development of hepatocellular carcinoma cells by down-regulating the PTEN/PI3K/AKT signalling pathway.

Authors:  Mingxiang Chang; Meimei Wu; Hanmin Li
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 7.  NF-κB and STAT3 - key players in liver inflammation and cancer.

Authors:  Guobin He; Michael Karin
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

8.  Optimization of competitively differentiated polymerase chain reaction in detection of HBV basal core promoter mutation.

Authors:  Xiao-Mou Peng; Lin Gu; Xue-Juan Chen; Jian-Guo Li; Yang-Su Huang; Zhi-Liang Gao
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

9.  Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2.

Authors:  Yu-An Yang; Gen-Mu Zhang; Lionel Feigenbaum; Ying E Zhang
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

10.  Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor.

Authors:  Vladimir V Kalinichenko; Michael L Major; Xinhe Wang; Vladimir Petrovic; Joseph Kuechle; Helena M Yoder; Margaret B Dennewitz; Brian Shin; Abhishek Datta; Pradip Raychaudhuri; Robert H Costa
Journal:  Genes Dev       Date:  2004-04-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.